Profiel
Leah Monteiro is currently the Vice President of Investor Relations & Communications at Solid Biosciences, Inc. Prior to her current position, she worked as the Senior Director of Communications & IR at KalVista Pharmaceuticals, Inc. from 2016 to 2021.
She also served as the Vice President of Investor Relations at DURECT Corp.
and as the Senior Manager of Investor Relations at Genzyme Corp.
Additionally, she worked as the Manager of Corporate Communications at Sesen Bio, Inc.
Actieve functies van Leah Monteiro
| Bedrijven | Functie | Begin |
|---|---|---|
| SOLID BIOSCIENCES INC. | Investor Relations Contact | - |
Eerdere bekende functies van Leah Monteiro
| Bedrijven | Functie | Einde |
|---|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Investor Relations Contact | 01-12-2021 |
| CARISMA THERAPEUTICS, INC. | Investor Relations Contact | 01-07-2016 |
| DURECT CORPORATION | Investor Relations Contact | - |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Investor Relations Contact | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Health Technology |
| DURECT CORPORATION | Health Technology |
| SOLID BIOSCIENCES INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |